Immunome to Present Preclinical Data on the Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

EXTON, Pennsylvania, September 30, 2021– (BUSINESS WIRE) – Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that uses its human memory B cell platform to discover and develop first-class therapeutic antibodies, today announced that ” She will prepare a poster presentation on the company’s anti-IL-38 antibody program at the upcoming joint meeting of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which will be held will be held from October 7 to 10, 2021.

Presentation details:

Title: “IMM20324, a first-class anti-interleukin-38 monoclonal antibody, rescues myeloid cell activation in vitro and induces robust anti-tumor responses in vivo. “

Authors: John P. Dowling, et al.

Abstract number: LBA022

Date hour : All poster presentations are made available by the conference when the meeting opens on October 7, 2021 at 9:00 a.m.ET

About Immunoma

Immunome is a biopharmaceutical company that uses its proprietary human memory B cell platform to discover and develop first-class therapeutic antibodies designed to change the way diseases are treated. The company’s initial goal is to develop therapies to treat oncology and infectious diseases, including COVID-19. Immunoma’s proprietary discovery engine identifies novel therapeutic antibodies and their targets by taking advantage of highly educated components of the immune system, memory B cells, in patients whose bodies have learned to fight their disease. For more information, please visit www.immunome.com.

Forward-looking statements

This press release includes certain disclosures that contain “forward-looking statements” intended to qualify for the “safe harbor” of liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to limit, express or implied statements regarding beliefs and expectations regarding the advancement of its COVID-19 therapeutic antibody programs, the execution of its regulatory, clinical and strategic plans, the next steps planned for IMM-BCP-01, including expectations regarding the therapeutic potential and the benefits thereof. Forward-looking statements may be identified by the words “anticipate”, believe “,” estimate “,” expect “,” intend “,” plan “,” plan “,” may “,” may “. , “Could”, “” should “,” seek “,” potential “and similar expressions. Forward-looking statements are based on Immunoma’s current expectations and are subject to uncertainties, risks and inherent assumptions which are difficult Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties associated with: the impact of the COVID-19 pandemic on business, operations, strategy, objectives and Immunome’s planned milestones; Immunome’s ability to execute its strategy with respect to its R&D efforts, IND submissions and other regulatory filings, the timing of such filings and government authorities’ comments thereon, study launch clinics and other anticipated milestones as and when forecast; the efficacy of Immunoma product candidates, including the possibility of further preclinical data and any clinical trial data may be inconsistent with data used to advance the product candidates; Immunome’s ability to finance its operations; Immunome’s dependence on suppliers; the competitive landscape; and the additional risks and uncertainties set out in more detail under “Risk Factors” in Immunome’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 25, 2021 , and elsewhere in Immunoma files and reports with the SEC. The forward-looking statements contained in this announcement are made as of this date, and Immunome assumes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except if it may be required under law.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20210930005888/en/

Contacts

Contact Immunoma
Corleen Roche
Financial director
Immunoma, Inc.
[email protected]

Investor contact
Laurence Watts
General manager
Gilmartin, LLC
[email protected]

Immunoma media contact
Megan McGrath or Nick Chang
MacDougall
781-235-3060
[email protected] or [email protected]

Source link

About Hector Hedgepeth

Hector Hedgepeth

Check Also

New Doctors | Mercy Health Services – Maryland Daily Record

Merciful health services recently added eight new physicians to its practices throughout the Baltimore area. …

Leave a Reply

Your email address will not be published. Required fields are marked *